Infectious Disease
RSSArticles
-
Daytime Sleepiness as a Stroke and Cardiac Risk Factor
Excessive daytime sleepiness appears to be an important risk factor for stroke. It is unknown whether this is related to obstructive sleep apnea or other mechanisms. -
Clobazam Tablets (ONFI™) CIV
A new benzodiazepine anticonvulsant was recently approved for the treatment of a difficult-to-treat childhood epilepsy (Lennox-Gastaut syndrome [LGS]). Clobazam is manufactured by Catalent Pharma Solutions and marketed as ONFI. -
Abstract & Commentary: Absent Influenza Vaccine Response in Rituximab-treated Lymphoma Patients
The concern regarding influenza infection is high in cancer patients since the rate of infection is considerably higher and mortality is four times greater than in the general population. -
Infectious Disease Alert March 2012 Issue in PDF
-
Antibiotics no Better than Placebo against Acute Rhinosinusitis
Garbutt and colleagues performed a randomized placebo controlled trial designed to evaluate the efficacy of antibiotic therapy in patients with a clinical diagnosis of acute rhinosinusitis at 10 primary care practices in St. Louis. -
Clinical Briefs in Primary Care supplement
-
Beta-Lactam Therapy of Urinary Tract Infection Fails Again
The increasing prevalence of antibiotic resistance in urinary pathogens has led Hooton and colleagues to examine the efficacy of a relatively broad spectrum orally administered cephalosporin in the treatment of uncomplicated cystitis. -
Abstract & Commentary: Patients Placed in Contact Isolation Are at Increased Risk for Delirium
To examine the association between being placed in contact isolation and delirium, Day and colleagues at the University of Maryland Medical Center reviewed administrative data on all patients admitted during a 2-year period ending in 2009. -
Cryptococcosis in Previously Normal Adults: NIH Study Seeking Participants
-
Pharmacology Watch: Dutasteride and Low-Risk Prostate Cancer
In this issue: New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.